| __timestamp | Apellis Pharmaceuticals, Inc. | Ionis Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2908166 | 20140000 |
| Thursday, January 1, 2015 | 6356782 | 37173000 |
| Friday, January 1, 2016 | 4303743 | 48616000 |
| Sunday, January 1, 2017 | 10463151 | 108488000 |
| Monday, January 1, 2018 | 22639184 | 244622000 |
| Tuesday, January 1, 2019 | 67046483 | 287000000 |
| Wednesday, January 1, 2020 | 139401000 | 354000000 |
| Friday, January 1, 2021 | 176771000 | 186000000 |
| Saturday, January 1, 2022 | 277163000 | 151000000 |
| Sunday, January 1, 2023 | 500815000 | 232600000 |
Infusing magic into the data realm
In the competitive landscape of biotechnology, understanding financial trends is crucial. Over the past decade, Ionis Pharmaceuticals and Apellis Pharmaceuticals have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Ionis Pharmaceuticals experienced a steady increase, peaking in 2020 with a 1,650% rise from 2014. However, their expenses saw a decline in subsequent years, dropping by 34% by 2022. In contrast, Apellis Pharmaceuticals demonstrated a more volatile pattern, with a staggering 17,100% increase from 2014 to 2023, reflecting their aggressive expansion and market penetration strategies. Notably, 2023 marked a significant surge for Apellis, with expenses doubling from the previous year. These trends highlight the strategic financial maneuvers of both companies as they navigate the dynamic biotech sector, offering insights into their operational priorities and market positioning.
Novo Nordisk A/S and Ionis Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Apellis Pharmaceuticals, Inc.
Comparing SG&A Expenses: BeiGene, Ltd. vs Apellis Pharmaceuticals, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Apellis Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Cytokinetics, Incorporated and Ionis Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Arrowhead Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Dynavax Technologies Corporation
Breaking Down SG&A Expenses: Ionis Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Alkermes plc or Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. and Amicus Therapeutics, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Apellis Pharmaceuticals, Inc. vs Protagonist Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Apellis Pharmaceuticals, Inc. and Taro Pharmaceutical Industries Ltd.